Introduction
Primary pulmonary arterial hypertension (PAH) is a rare and fatal disease with enigmatic molecular origins. 1 It is pathologically characterized by progressive pulmonary arterial remodelling, 2 leading to an abnormal elevation in pulmonary arterial pressure of greater than 25 mmHg. 3 Current treatment strategies for this disease are mainly palliative, and therefore do not significantly improve long-term survival. 4 As such, new therapies are clearly needed to ameliorate the irreversible pulmonary arterial remodelling observed in PAH patients. The aberrant accumulation of ECM proteins contributes to pulmonary arterial remodelling in PAH. Specifically, exposure of the pulmonary vasculature to hypoxic stimuli results in the excessive secretion of profibrotic factors such as TGF-b1, thereby promoting forced ECM production and decreased ECM degradation. 5 While the molecular mechanisms that regulate ECM deposition in the pulmonary vasculature in PAH have not been fully elucidated, RAGE signalling was previously implicated in the accumulation of ECM proteins. During neointimal formation upon acute vascular injury, RAGE/S100B signalling is essential for the expression of ECM molecules. 6 Furthermore, RAGE/HMGB1 signalling contributes to the pathogenesis of cardiac troponin I-triggered myocardial fibrosis and bleomycin-induced lung fibrosis. 7, 8 Based on these previous results, we hypothesized that the activation of RAGE activity contributes to the ECM modifications observed in PAH. RAGE and two of its ligands, HMGB1 and S100/calgranulins, play essential roles in the maintenance of lung homeostasis and pulmonary vascular tone. 9 During hypoxia, increased HIF-1 can bind the RAGE promoter, leading to upregulation of RAGE within the lung. 10 In parallel, HMGB1 and S100B, a member of the S100-calgranulin family, are also upregulated in response to hypoxia and inflammation, which underlies and accounts for the development of pulmonary hypertension. 11, 12 Further proteomic analyses of lung tissues from primary PAH patients have shown increased RAGE expression, particularly in the pulmonary arterial smooth muscle layer, which positively correlates with disease severity. 13, 14 Additionally, sRAGE, which acts as a decoy receptor and reflects the extent of cellular RAGE expression and activation, 15 has been observed in the serum of PAH patients and mice. 16, 17 Experimental evidence demonstrates that RAGE inhibition reverses PAH phenotype of hPASMCs in vitro and in both monocrotaline-and HySu-induced PAH in vivo, 14, 18 whereas genetic deletion of RAGE only manifests as a reduction of right ventricle hypertrophy in wild-type mice exposed to chronic hypoxia. 19 Indeed, chronic hypoxia-induced PAH in mice fails to recapitulate the severe vascular lesions akin to human PAH. Unfortunately, this shortcoming has limited the suitability of genetically modified mouse models to characterize the molecular pathophysiology of PAH. 20 Thus, it is important to define the role of RAGE and its ligands for pulmonary vascular remodelling and identify the signalling pathways using a combination of RAGE-knockout and HySu-induced PAH mouse models that display complex vascular remodelling similar to that observed in human PAH, including ECM protein synthesis and deposition.
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HMGB1 binds and activates TLR2, TLR4, and TLR9, and plays a critical role in the development of PAH. 19, 21 Clinical data show that HMGB1 serum concentrations were higher in idiopathic PAH patients and associated with indicators of disease severity. 19 Moreover, experimental results demonstrate that HMGB1 expression is increased in both concentric and plexiform lesions of remodelled pulmonary arteries from iPAH patients, and that the interaction between HMGB1 and TLR4 exacerbates human pulmonary artery endothelial cell (HPAEC) dysfunction and inhibits their migration. 19, 22 However, since several studies suggest a role for the RAGE axis in both experimental and human PAH, and RAGE and HMGB1 are abundantly expressed in the pulmonary arterial smooth muscle layer, 14, 19, 23 it is thus paramount to precisely define the role of these factors in pulmonary vascular smooth muscle cell dysfunction in PAH pathogenesis.
Here, we report that the levels of RAGE and two of its ligands, S100B and HMGB1, were upregulated in both human and murine PASMCs exposed to hypoxia and in the pulmonary arteries (PAs) of HySuinduced PAH mice. Notably, RAGE disruption conferred protection against HySu-induced PAH and reduced ECM deposition via ERK/p38-dependent TGF-b1 pathway inhibition. In addition, interaction between HMGB1 and RAGE, but not TLR4, promoted ECM protein deposition in PASMCs. Furthermore, sRAGE serum concentrations were significantly elevated in patients with idiopathic PAH (iPAH) compared to healthy controls, and thus could be a useful biomarker for RAGE-related PAH. Taken together, these observations provide novel mechanistic insights into ECM protein regulation and indicate that RAGE is a potential therapeutic target for PAH.
Methods

Study population
The diagnosis of pulmonary hypertension (PH) was based on a mean pulmonary arterial pressure of > _25 mmHg, as confirmed by right heart catheterization at rest. 24 The iPAH group was characterized by a lack of underlying causative disease, according to the criteria of the 5th World Symposium of PH (Nice, France, 2013). In total, 23 iPAH patients who underwent right heart catheterization were enrolled between March 2009 and September 2015 in addition to 23 controls who were matched with respect to age, gender, and ethnicity. In iPAH patients, the diagnosis of PH was made on the basis of pulmonary arterial systolic pressure (PASP) estimated by echocardiography and subsequently confirmed by right cardiac catheterization before making a treatment decision. Owing to the heterogeneity in the role of RAGE in the pathogenesis of various diseases, patients with comorbidities such as chronic or intercurrent inflammatory diseases, left heart disease, diabetes mellitus, ongoing liver disease, malignancies, and renal insufficiency, were excluded. Basic demographic and iPAH-associated symptoms are presented in Table 1 .
All subjects provided informed written consent, and the study conformed to the principles outlined in the Declaration of Helsinki. The study was approved by the Ethics Review Board at Ruijin Hospital (Shanghai Jiao Tong University).
Experimental design and procedures
Detailed descriptions of the experimental design, as well as the methods used for hemodynamic measurements, cell culture, western blotting, real-time PCR, serum protein detection, RAGE overexpression, histological analysis, immunohistochemistry, immunofluorescence, siRNAmediated gene silencing, and immunoprecipitation are provided online as Supplementary material online.
Statistical analysis
Data are expressed as means ± S.E.M or as median and interquartile range for all analyses. Chi-square testing was used to analyse discrete variables. Correlations were assessed using Pearson's correlation analyses. Means between two or more groups were compared using twotailed Student's t-tests or two-way ANOVA with Bonferroni's post hoc testing, respectively. Comparisons of 6MWD, sRAGE, and LVEF at baseline and follow-up were performed via paired t-tests. P < 0.05 was considered statistically significant.
Results
3.1 RAGE and its ligands, S100B and HMGB1, are upregulated in PAs in HySuinduced PAH mice RAGE, S100B, and HMGB1 mRNA levels were strikingly elevated in lung tissues and PAs from HySu-treated mice and in cultured mPASMCs and hPASMCs exposed to hypoxia when compared to normotensive counterparts ( Figure 1A -D) and were primarily distributed in vascular smooth muscle layers as determined by immunohistochemical analysis ( Figure 1E ).
In addition, we measured the expression of RAGE and two of its ligands RAGE in pulmonary arterial hypertension in mPASMCs and hPASMCs by immunofluorescence staining in vitro.
After exposure to hypoxia (1%O 2 ) for 24 h, both cell types exhibited elevated expression of RAGE, S100B, and HMGB1 compared to the controls (see Supplementary material online, Figure S1A -F). Moreover, sRAGE, S100B, and HMGB1 serum concentrations were significantly higher in response to HySu than in normoxic conditions ( Figure 1F ) and correlated with right ventricular systolic pressure (RVSP) and the ratio of the right ventricular wall to the left ventricular wall plus the septum (RV/LV þ S) (see Supplementary material online, Figure S2A -C).
Deletion of RAGE confers protection against HySu-induced PAH in mice
Chronic HySu treatment produces PAH in mice that display pathological processes of PAs akin to human iPAH, and the cytokine profiles of these mice are similar to those of iPAH patients. 20 After a 3-week exposure to
HySu, mice developed a strikingly higher RVSP and weight ratio of RV/LV þ S compared with normoxic control mice ( Figure 2A and B).
Mean systemic arterial pressure did not differ significantly between RAGE -/-mice and wild-type mice in normoxia or HySu conditions (see Supplementary material online, Figure S3A ). A decrease in body weight was detected after 3 weeks of exposure to HySu, but there was no significant difference between wild-type mice and RAGE -/-mice (see Supplementary material online, Figure S3B ). Intriguingly, RAGE -/-mice developed significant reductions in RVSP (37.13 ± 1.30 mmHg vs. 30 .63 ± 1.28 mmHg, P < 0.05) ( Figure 2A ) and RV/LV þ S (41.31 ± 1.54% vs. 35 .19 ± 1.20%, P < 0.05) ( Figure 2B ) compared with wild-type mice, as well as reduced medial wall thickness ( Figure 2C and D). Moreover, exposure to HySu for 3 weeks diminished the number of fully muscularized vessels, but increased the number of non-muscularized vessels ( Figure 2E ).
RAGE mediates the deposition of ECM proteins in PAs via the activation of TGF-b1
Vascular remodelling of PAs in primary pulmonary hypertension is characterized by the aberrant deposition of ECM proteins such as fibronectin and collagen. Figure S4 ) and mRNA expression analysis of lung tissues ( Figure 3D ). Previous studies demonstrated that RAGE-induced TGF-b1 production plays a pivotal role in ECM protein accumulation. 7, 25 By binding to its receptor, TGF-b1 phosphorylates SMAD2/3, which then dissociates from the receptor complex to form a heterotrimeric complex with Smad4 and translocates to the nucleus to act as a transcription factor for TGF-b-dependent genes. 26 As such, we next determined whether TGFb1 changed in RAGE -/-mice exposed to HySu. Based on ELISA analysis, the levels of TGF-b1 were significantly decreased in the lung lysates of RAGE -/-mice compared to wild-type counterparts after exposure to HySu ( Figure 4A) . Moreover, the PAs from HySu-stimulated RAGE -/-mice showed phosphorylated SMAD2/3 mainly localized to the cytoplasm rather than the nucleus, further supporting that RAGE-mediated TGF-b1 is a potent modulator of ECM synthesis in PH ( Figure 4B and C).
We also detected decreased TGF-b1 levels ( Figure 4D and see Supplementary material online, Figure S5A ) accompanied by diminished SMAD2/3 phosphorylation ( Figure 4E and F and see Supplementary material online, Figure S5B -D) and downstream production of collagen I, fibronectin, and tenascin C in hypoxia-stimulated RAGE -/-mPASMCs ( Figure 4G and H) and hPASMCs preincubated with an anti-RAGE antibody (see Supplementary material online, Figure S6 ). 27, 28 To determine whether these pathways were activated in pulmonary hypertension, we evaluated the phosphorylation levels of ERK1/2, JNK, and p38 in cultured mPASMCs. Notably, exposure to hypoxia (1%O 2 ) for 24 h increased ERK1/2, JNK, and p38 phosphorylation in mPASMCs ( Figure  5A and B). Interestingly, ERK1/2 and p38 phosphorylation in cultured RAGE -/-PASMCs was depressed under hypoxic stress, whereas JNK showed no significant differences ( Figure 5A and B) . Moreover, RAGE reconstitution rescued ERK1/2 and p38 phosphorylation, but not that of JNK ( Figure 5C and D) , and restored hypoxia-induced TGF-b1 signalling in mPASMC cultures as shown by increased SMAD2/3 phosphorylation and the upregulation of collagen I, fibronectin, and tenascin C ( Figure 5E and F and see Supplementary material online, Figure S7 ). Further, TGF-b1 signalling was significantly suppressed by pretreatment with the p38 kinase inhibitor SB203580 and ERK1/2 inhibitor PD98059, while no significant effects were detected with the JNK inhibitor SP600125 ( Figure 5G -I and see Supplementary material online, Figure S8 and 9).
RAGE ligation enhances hypoxia
3.5
Interaction between S100B, HMGB1, and RAGE, but not TLR4, promotes the ECM accumulation S100B-RAGE and HMGB1-RAGE signalling were monitored in mPASMCs to determine their respective participation in ECM accumulation. Notably, wild-type mPASMCs stimulated with HMGB1 or S100B showed elevated ERK1/2 and p38 phosphorylation, and a corresponding accumulation of ECM proteins ( Figure 6A and B and see Supplementary material online, Figure S10 ). Interestingly, HMGB1 and S100B-induced ERK1/2 and p38 phosphorylation and ECM accumulation were attenuated in RAGE -/-mPASMCs ( Figure 6A and B and see
Supplementary material online, Figure S10 ). HMGB1 has been shown to promote TLR-dependent PAH development by contributing to endothelial dysfunction and inflammation, and blocked HPAEC migration via a TLR4-and interferon response factor 3 (IRF3)-dependent mechanism. 19, 22 As such, we further explored the effects of TLR2, TLR4, TLR9, and HMGB1 on ECM accumulation in PASMCs. Interestingly, qRT-PCR analysis revealed that both hPASMCs and from wild-type (WT) mice exposed to normoxia or HySu (n = 6-7 per group), (B) pulmonary arteries (PAs) of mice exposed to normoxia or HySu (n = 6 per group), (C) primary mPASMCs exposed to normoxia or 1% O 2 (n = 6 per group), and (D) primary hPASMCs exposed to normoxia or 1% O 2 (n = 6 per group). (E) Representative images of RAGE, S100B, and HMGB1 expression in lung tissues from WT mice exposed to normoxia or HySu, as determined by immunohistochemistry analysis. Scale bar: 20 lm. (F) Serum sRAGE, S100B, and HMGB1 levels were measured in the control and HySu mice (n = 8 per group). Data are presented as means ± SEM. *P < 0.05 vs. normoxic controls analysed by two-tailed Student's t-test. Figure S11 ), and that TLR4 expression was not significantly altered in hypoxic PASMCs, RAGE -/-mPASMCs, or hPASMCs preincubated with RAGE neutralizing antibody compared with the normoxic controls ( Figure 6C and D). To determine whether HMGB1 interacts with RAGE or TLR4, anti-HMGB1 immunoprecipitations were probed with antibodies RAGE or TLR4. Interestingly, HMGB1 interacted with both RAGE and TLR4 in hypoxic and normoxic mouse and human PASMCs ( Figure 6E and F); however, hypoxia substantially increased interaction affinity between HMGB1 and RAGE, but not TLR4 ( Figure 6E and F and see Supplementary material online, Figure S12) . Moreover, TLR4 knockdown failed to abrogate ERK1/2 and p38 phosphorylation, TGF-b1 expression, or ECM deposition after HMGB1 stimulation, further supporting that the HMGB1 and RAGE interaction was responsible for ECM accumulation in mPASMCs ( Figure 6G and H and see Supplementary material online, Figure S13 ). Finally, TLR4-deficient mice showed decreased RVSP and RV/LV þ S in HySu-induced PAH (see Supplementary material online, Figure S14A and B), but no significant differences in collagen I or fibronectin accumulation in PAs ( Figure  6I and J and see Supplementary material online, Figure S14C and D), or in lung tissue (see Supplementary material online, Figure S14E -G).
sRAGE, S100B, and HMGB1 serum levels are elevated in patients with iPAH
The serum levels of sRAGE, S100B, and HMGB1 were markedly higher in patients with iPAH than in controls ( Figure 7A) . Notably, there was a significant positive correlation between serum sRAGE concentrations and mPAP in patients with iPAH (R 2 = 0.4542, P = 0.0004) ( Figure 7B ).
Likewise, we observed a positive correlation between plasma S100B, Figure S15A) . Interestingly, the serum sRAGE levels of patients with a 6-min walking distance (6MWD) of < 375 m and with WHO functional classes III and IV were significantly higher than those in patients with a 6MWD of >375 m and WHO functional classes I and II ( Figure 7C) . These results indicate that sRAGE may be related to PH severity since 6MWD and WHO functional classification are independent predictors of survival and clinical deterioration for patients with PH. 29 After a mean follow-up duration of 24 months (range, 13-41 months), 11 patients were censored, and 2 iPAH patients had died. We therefore examined the sRAGE levels in the remaining 10 patients treated with prostacyclin analogues (including 5 patients taking a combination of phosphodiesterase-5 inhibitors), which are specific drugs for PAH therapy. 29 Significantly, these patients showed decreased WHO functional classifications (2.8, 95% CI: 2.34-3.25 to 1.9, 95% CI: 1.37-2.43, P = 0.009), increased 6MWD ( Figure 7D) , and improved LVEF (see Supplementary material online, Figure S15B ). Thus, disease-specific medication significantly decreased sRAGE serum levels in iPAH patients ( Figure 7E ), suggesting that sRAGE may serve as a biomarker of effective medical treatment of PAH. 
Discussion
In this study, we demonstrated that RAGE expression was upregulated in PAs isolated from HySu-induced PAH model mice, as well as hypoxic human and mouse PASMCs. Similarly, the RAGE ligands S100B and HMGB1 showed increased formation/deposition in PAs of an experimental PAH mouse model and elevated concentrations in the serum of iPAH patients. Notably, RAGE disruption by neutralizing antibody or genetic deletion attenuated ECM protein accumulation and thus reduced PAH progression. Furthermore, RAGE ligation enhanced hypoxia-stimulated TGF-b1 signalling and fibrotic protein expression in PASMCs and PAs via ERK1/2 and p38 MAPK pathway activation. In addition, interaction between HMGB1 and RAGE, but not TLR4, mediated ECM accumulation in PASMCs, suggesting that RAGE plays a critical role in the induction and development of pulmonary vascular remodelling and may be a putative therapeutic target in primary PAH.
RAGE-mediated ECM proteins accumulation
Accumulating evidence demonstrates that RAGE signalling plays a pivotal role in the vascular remodelling. 14, 23 RAGE is a single transmembrane receptor in the immunoglobulin superfamily with a diverse repertoire of ligands and implicated in several signalling pathways, including vascular fibrosis. 6, 25 In addition, RAGE is constitutively expressed in the lung, particularly in the small arteries and arteriolar capillaries, suggesting that it may serve an important role in lung homeostasis. 9 We found that RAGE was strikingly upregulated in human and murine PASMCs subjected to hypoxic conditions in vitro and in PAs from HySu-induced PAH mice. Moreover, RAGE disruption attenuated pulmonary vascular remodelling, ECM protein accumulation, and thickening of the smooth muscle layer in PAs to effectively block PAH progression. These observations indicate that interaction between RAGE and its ligands mediated ECM protein deposition and exacerbated pulmonary hypertension. The fact that these effects were seen in the HySu-induced PAH model that mimics complex neointimal development and human PAH progression supports the hypothesis that RAGE plays a critical role in PAH development. Furthermore, we demonstrated a direct interaction between RAGE, TLR4, and HMGB1 in PASMCs, and decreased accumulation of ECM in hypoxic RAGE -/-mPASMCs with S100B and HMGB1 stimulation. Meanwhile, no differences in TLR4 expression were observed in normoxic or hypoxic WT and RAGE -/-mPASMCs, and knockdown or genetic disruption of TLR4 had no overt influence on accumulation of ECM proteins, indicating that the interaction between HMGB1 and RAGE, in particular, was responsible for ECM accumulation in PASMCs. Consistent with these observations, RAGE, but not TLR2, 4, or 9, is critical for the effects of HMGB1 on collagen upregulation in liver fibrosis. 30 However, others have reported that RAGE -/-mice only display reduced right ventricular hypertrophy, compared with wild-type mice, after exposure to chronic hypoxia, 19 and HMGB1 is known to facilitate PH by inhibiting HPAEC migration via a TLR4-dependent mechanism. 22 These discrepancies are probably ascribed to differences in PAH models or cell type, and perhaps different downstream signalling is mediated by RAGE and TLR4. Nevertheless, RAGE blockade with a soluble, truncated form of RAGE (sRAGE) modulates vasoreactivity and compliance of the pulmonary arteries. 18 Our results are consistent with previous reports identifying RAGE signalling as an important mediator of vascular tone in PH, in which it stimulates ECM accumulation and promotes PA stiffness. 31 Interestingly, sRAGE levels were increased in iPAH patients, and were subsequently reduced in response to effective treatment. These observations indicate that sRAGE is a potential biomarker for diagnosis and estimation of therapeutic efficacy. However, many patients refuse to undergo the invasive right-sided catheter procedure after effective treatment owing to its associated risks, and thus the correlation between mPAP and sRAGE in response to effective therapy cannot be determined. Moreover, another limitation of our prospective study was the small follow-up population (n = 10). Thus, our findings should be confirmed by a prospective, multi-centre study with a larger patient population.
The activating ligands of RAGE, S100B, and HMGB1
Previous studies have suggested that hypoxia and proinflammatory stimuli enhance RAGE expression, which likely stimulates the sustained expression of S100B and HMGB1 via a positive feedback loop. 9, 10 Indeed, S100B and HMGB1 are expressed in a wide range of cell types, including vascular smooth muscles and immune cells. 9 Hypoxia induced upregulated S100B and HMGB1 deposition in the pulmonary vascular smooth muscle layer of HySu-induced PAH mice. Moreover, we found significantly higher S100B and HMGB1 serum concentrations in iPAH patients and HySu-induced PAH mice as compared to controls. Other investigators did not detect elevated HMGB1 levels in PH patients, 16 which was probably due to the different PH groups investigated and number of patients enrolled in this previous study. In addition, the S100 family of proteins consists of 25 relatively small calcium binding proteins such as S100A8/A9 and S100A12 that possess a broad spectrum of intracellular and extracellular functions in cardiovascular disease. 32 Serum S100A12 concentrations but not S100A9, were previously found to be elevated in PAH patients 23, 33 ; however, we did not detect any overt differences in ECM accumulation in hPASMCs upon S100A12 stimulation (see Supplementary material online, Figure S16) . Thus, the subtypes of S100 protein-mediated cellular functions are disease-specific and context-dependent and should be examined in further studies. Together with the increased expression of RAGE in PAs in response to HySu, we propose that the overlapping and enhanced ligand-receptor expression serves a novel axis to sustain PASMC activation and enhance ECM protein accumulation.
TGF-b1 signalling
TGF-b1 signalling is elevated in iPAH patients and animal models, and is necessary for PAH progression.
5,34 Correspondingly, we observed increased TGF-b1 signalling in HySu-induced PAH mice and hypoxic mPASMCs and hPASMCs. Interestingly, RAGE, but not TLR4, deficiency suppressed TGF-b1 pathway activation and attenuated ECM accumulation in PASMCs and PAs, suggesting that RAGE is a key molecular target to restore PAs homeostasis. Similarly, smooth muscle cells produced TGF-b1 in response to interactions occurring during RAGE ligation, which likely mediate vascular fibrosis and arterial stiffness. 35 Furthermore, ERK1/2 and p38 phosphorylation was suppressed in RAGE -/-PASMC cultures subjected to hypoxia, and RAGE reconstitution restored ERK1/2 and p38 phosphorylation, consistent with TGF-b1 signalling alterations. Collectively, these observations indicate that RAGE-mediated TGF-b1 production following hypoxic stress occurs via the ERK/p38 MAPK pathways.
Clinical implications
In summary, we used in vivo and in vitro models to show that the sustained expression of RAGE and its ligands S100B and HMGB1 facilitate pulmonary hypertension. Additionally, we demonstrated that RAGE inhibition confers protection against pulmonary hypertension. Thus, our findings support the conclusion that sRAGE serum levels may serve as a useful biomarker for RAGE-related PAH, and that RAGE blockade may be a promising therapeutic strategy to treat this disease.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
